~~<i id='EF8C42AB56'><strike id='EF8C42AB56'><tt id='EF8C42AB56'><pre id='EF8C42AB56'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

Wikipedia

author：fashion 2025-09-29 09:29:48 - browse：125

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

A couple billion here, a couple billion there, and pretty soon Eli Lilly hopes it will be talking about real money.

Eli Lilly agreed to purchase Point Biopharma Tuesday morning for $1.4 billion, a 90% premium, adding to its pipeline of cancer drugs. Point is developing cancer drugs that deliver a focused dose of radiation to tumor cells. Data for its lead medicine, for prostate cancer, are expected in the fourth quarter. It is also developing a drug for neuroendocrine tumors.

Point operates a 180,000-square-foot radiopharmaceutical manufacturing facility in Indianapolis, and a radiopharmaceutical research and development center in Toronto.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

explore

leisure time

explore

Wikipedia

focus

MollyFerguson/STATThoughtsaboutCytokineticsafterWednesdaynight’sfinancingannouncement:1.Managementis

WSS

H5N1 bird flu outbreak: Second human case reported, in Michigan

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

As a primary care physician, here's how I hope to partner with AI

Scientists unlock the key to scar

Listen: More tumult at BIO & coercive care for sickle cell patients

Bird flu surveillance in wastewater gets boost from consortium

leisure time

Wikipedia

explore

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Citing H5N1 threat, CDC urges peak flu monitoring this summer

Anesthesiologist group: stop taking Ozempic before surgery

Change Healthcare cyberattack outage could last weeks

After affirmative action ruling, medical educators look to 'holistic review'

At flashy new research hub, AstraZeneca lays out ambitious growth goals

Duchenne breakthrough therapy leaves behind pioneering families

Biotech companies concerned about China biosecurity crackdown

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Bird flu surveillance in wastewater gets boost from consortium

explore

ASCO eve: Let’s set the table for this year's meeting

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

Digital health: a case of mistaken identity

In search for therapies for solid tumors, companies turn to claudin

Obesity now affects over 1 billion people worldwide, study finds

House looks to weaken Medicare negotiation

leisure time

explore

Wikipedia

focus